NanoBio Licenses RSV Vaccine Tech

Ann Arbor, MI-based NanoBio today announced it has licensed an antigen from the National Institutes of Health (NIH) that it says represents a significant step forward in the development of a vaccine for respiratory syncytial virus (RSV). Currently, there are no approved vaccines for RSV, an infection that sends 75,000 to 125,000 infants under 1 to the hospital each year in the United States. The agreement provides NanoBio with global rights to NIH’s new RSV antigen, which the Ann Arbor company will incorporate into a nose spray vaccine, using its proprietary oil-and-water nano-emulsion technology.

Trending on Xconomy